Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
8,593 total articles
Natera (NTRA) is a market leader in genetic diagnostics with early traction in MRD and durable NIPT market share. Recent clinical readouts and analyst commentary point to accelerating MRD revenue and an expanding addressable market. Valuation is rich but not unreasonable for high-growth diagnostics; this trade targets upside toward analyst consensu…
Smithfield (SFD) combines strong cash flow, a 4%+ dividend and recent branded M&A, yet trades at ~10x earnings and an EV/EBITDA below 7. We think the market is overlooking branded upside and accretive M&A; buy SFD at $26.00 with a $30.00 target and $24.00 stop for a mid-term (45 trading days) swing.
Damora Therapeutics ($25.97) is a small, tightly staffed biotech with a clinical-stage mindset and a surprisingly clean balance sheet. For traders willing to stomach binary clinical outcomes, the stock offers a defined risk entry with clear upside to the prior 52-week high if a CALR-focused program shows early promise or the company announces partn…
KKR is a diversified alternative asset manager and insurance operator with a $85.3B market cap, a durable fee-bearing franchise and active capital recycling. At $95.00 the stock is trading well below prior highs and reflects short-term private-markets worries; we view the setup as a long-term trade with asymmetric upside driven by asset realization…
CVR Energy (CVI) is a leveraged refining complex with renewable diesel and fertilizer businesses. Margins have been weak and profitability remains negative, but macro-driven widening crack spreads and recent technical weakness create a defined risk-reward swing trade. Entry $31.50, stop $28.00, target $38.00 — mid-term (45 trading days), medium ris…
Goldman Sachs is the market’s best-positioned bank to monetize the coming SpaceX IPO after being named a lead underwriter. Coupled with a historically strong quarter in capital markets, the stock looks set to benefit from fees, higher trading flows, and renewed investor appetite. We outline a tactical long trade over the next 45 trading days with e…
McDonald’s (MCD) is trading materially off its February highs and now sits at a P/E near 23 with a $198.5B market cap, a 2.6% yield, and >$6.6B of free cash flow. Fundamentals and the franchise model remain intact; this is a tactical long trade for mean reversion into value and improved traffic, with defined risk controls.
Corning (GLW) is widely framed as an AI-infrastructure play thanks to exploding demand for fiber and connectivity. That’s true, but beneath the headlines are three underappreciated segments - Optical Communications scale-up, Automotive ceramics, and Life Sciences materials - that give the company a multi-legged growth story. Valuation is rich (mark…
Advanced Micro Devices is trading at cycle highs after a powerful run. Fundamentals and AI-driven demand argue for more upside, but valuation and intensifying competition require a disciplined trade: entry $505.00, stop $475.00, target $560.00 on a mid-term (45 trading days) horizon.
Flowers Foods (FLO) is an operationally challenged but cash-generative bakery operator. Management's dividend reset frees roughly $100M to accelerate deleveraging and productivity programs. At ~ $7.80 today, the shares trade at low revenue and cash-flow multiples with meaningful upside if cost saves and volume stabilization occur. This is a tactica…
Sandisk has re-rated on AI-driven NAND demand, strong margin profile and a thin short book. Even if spot NAND prices ease, fundamentals and momentum can keep the stock moving higher. This trade idea lays out an entry at $1600, a stop at $1400 and a target of $2000 with clear horizons and risk controls.
Nebius has gone from deep-value to market leader narratives in a matter of months. Revenue acceleration, improving margins, and strategic partnerships around data center power have turned the name into a high-growth, profitable infrastructure franchise. Technicals still show momentum and shorts are sizable but manageable. I rate NBIS a Strong Buy w…
Infleqtion (INFQ) is trading on momentum following federal funding headlines and a sharp volume breakout. The business is nascent and losses are real, but technicals, rising volume, and a pipeline tied to neutral-atom quantum hardware create a defined, asymmetric trade: enter near $16.00, stop $12.00, target $25.00 with a mid-term hold. This is a h…
PodcastOne (PODC) has accelerated revenue and profit guidance after selling original IP and expanding AI-driven distribution. Market cap sits near $130M with EV/Sales ~2.1x and free cash flow turning positive. Technicals show a breakout, but RSI is extended. We lay out a mid-term swing trade with concrete entry, stop and target and an explicit risk…
REPSOL ADR (REPYY) pulled back to $25.88 but sits within striking distance of its short-term moving averages. Recent operational wins in renewables and an upbeat quarter set the stage for a swing-long trade with defined entry, stop and target.
Enterprise Products Partners (EPD) trades near $38.50 with a 5.5%+ yield, solid free cash flow and an infrastructure 'toll-taker' business that holds up in volatile oil markets. Technicals show mild bullish momentum and valuation metrics (P/E ~14, EV/EBITDA ~12) suggest the stock is priced for steady, not spectacular, growth. This trade idea lays o…
Hancock Whitney (HWC) trades at a modest P/E and P/B after recent M&A activity and signs of margin expansion. With a $5.53B market cap, steady free cash flow and a 2.8% yield, the stock is attractive for a mid-term swing trade. Entry $68.50, target $77.00, stop $63.00.
Alphabet is the best-positioned mega-cap to capture the next wave of AI monetization. Recent product launches and renewed enterprise traction make a disciplined long at $389 a favorable risk-reward for a 180-trading-day trade.
MPLX combines a near-8% yield, solid cash flow generation and a pipeline of funded projects to support mid-single-digit distribution growth. At $56.60 the stock offers ~10-15% upside to my 180-day target while keeping a buffer for a 9-10% stop. I outline a clear entry, stop and target along with the catalysts and the risks that could derail the tra…
PETROBRAS (PBR) trades at a sub-7x P/E with a >5% yield and visible cash generation from pre-salt production. We outline a long trade for income-seeking, value-oriented investors: entry at $19.47, stop at $17.00, target $22.50 over a long-term horizon (180 trading days). Key risks include oil-price weakness, policy interference, refining margin pre…
Archer (ACHR) has been punished largely for one clear reason - the market has been pricing a high cash burn and late revenue ramp into the stock. With the company now completing Phase 3 of FAA Type Certification and limited early flights imminent, the risk narrative is shifting from 'can they get certified' to 'how quickly can they commercialize.' …
Lululemon is trading at historically low multiples after a year of margin pressure and macro headwinds. With a market cap around $15.2B, free cash flow near $922M and return on equity above 30%, the risk-reward now favors long-term buyers prepared to tolerate volatility through upcoming earnings and early stages of international expansion.
Tenet Healthcare (THC) has taken heat from regulatory headlines, but recent results show durable cash flow, raised EPS guidance and attractive valuation metrics. We present a mid-term swing trade (45 trading days) that buys the dip around $175 with a $168 stop and $210 target—a risk-reward setup that leans on Tenet's EBITDA strength, free cash flow…
Crexendo ($CXDO) just cleared its 52-week high on heavy volume, beating short-term sellers and re-rating on growth and cash flow. The business is small but profitable, and recent price action creates a defined trade: enter at the market, protect with a tight stop under near-term support, and target a gain that pays well for the risk taken.
We upgrade Expedia (EXPE) to a buy for a mid-term trade. Despite region-specific travel disruptions, ADR expansion and product distribution gains are lifting revenue and booking value. The company trades on attractive free cash flow multiples, has a manageable balance sheet, and is showing improving retail momentum. Entry at $223.44, target $260, s…
